Efficacy of DCBT 2345 - an ayurvedic compound in treatment of type 2 diabetic patients with secondary failure to oral drugs - randomized double blind placebo control study

Abstract

The objective of this study was to determine the efficacy of DCBT 2345 - an ayurvedic compound, in the management of diabetes of type 2 diabetic patients with secondary failure to oral hypoglycemic agents. A randomized, double blind, single center study of six months duration was carried out. 44 type 2 diabetic patients who satisfied the inclusion criteria were recruited for the study. Out of 44 patients, 30 completed the trial. 15 in the DCBT 2345 arm and 15 in the placebo arm. End points of the study included fasting and post prandial plasma glucose and glycosylated hemoglobin levels. There was no significant reduction in the fasting and postprandial plasma glucose levels in both the groups (placebo and DCBT 2345). However there was a significant reduction in the glycosylated hemoglobin levels (p = 0.037) in the DCBT 2345 group. No adverse events were noted in patients treated with DCBT 2345. Our study suggest that DCBT 2345 exerts a mild hypoglycemic action in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.